Long-term study of memory and aging with blood and spinal fluid samples
Studies blood and spinal fluid tests in adults with memory problems and healthy adults.
Plain-language title generated from the registry record
Registry title: DC Longitudinal Study on Aging and Specimen Bank
Key facts
- Where
- Washington D.C., United StatesSee the site
Where in United States
- Georgetown University Memory Disorders ProgramWashington D.C., United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Georgetown University
- Trial code
- NCT03702907
- Record updated
- 24 October 2019
- Original description
The Georgetown University Memory Disorders Program, part of the Department of Neurology, is conducting pilot studies of the feasibility of various diagnostic tests for Alzheimer's disease, mild cognitive impairment and other neurodegenerative diseases. Further, this study is assessing longitudinal changes in biological, lifestyle, and cognitive assessment collection.Read full original descriptionShow less
DC Longitudinal Study on Aging and Specimen Bank
The Georgetown University Memory Disorders Program, part of the Department of Neurology, is conducting pilot studies of the feasibility of various diagnostic tests for Alzheimer's disease, mild cognitive impairment and other neurodegenerative diseases. Further, this study is assessing longitudinal changes in biological, lifestyle, and cognitive assessment collection.
The primary goal of this study is to examine the feasibility of biochemical assays, genetic testing, and cognitive and lifestyle assessments in the ante-mortem diagnosis of Alzheimer's disease, mild cognitive impairment and other neurodegenerative diseases. This research involves genetic and cognitive status testing but the findings will not be shared with research subjects. This will be accomplished ex vivo using blood, and/or cerebrospinal fluid (CSF) specimens from patients with a diagnosis of probable Alzheimer's disease, mild cognitive impairment, or other neurodegenerative diseases and from normal controls.
Inclusion: Age 45 and older; Subjects within the age range of 45-50 years old must have a first degree relative with a neurodegenerative disease.
Exclusion: Individuals under 45 years of age.